Astra Faces Off With FDA on Copies of $7 Million-a-Day DrugBy and
Prices may drop by 85 percent if generic Crestor is available
Court ruling is pending on Astra’s lawsuit to block generics
AstraZeneca Plc is making a final push to protect a drug that makes $7 million a day in the U.S. against cheaper copies as pressure mounts on the U.K. drugmaker to meet its own projections of almost doubling revenue.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.